Holen Sie sich die Stockscreener-App
3.17
3.94%
-0.13
Vorhandelsmarkt:
3.15
-0.02
-0.63%
Schlusskurs vom Vortag:
$3.30
Offen:
$3.26
24-Stunden-Volumen:
41,102
Relative Volume:
0.02
Marktkapitalisierung:
$7.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$1.52M
KGV:
-0.5015
EPS:
-6.3213
Netto-Cashflow:
$-1.14M
1W Leistung:
-4.80%
1M Leistung:
-35.44%
6M Leistung:
-66.85%
1J Leistung:
-88.38%
1-Tages-Spanne:
$3.04
$3.3499
1-Wochen-Bereich:
$3.04
$3.53
52-Wochen-Spanne:
$0.6254
$74.94
Psyence Biomedical Ltd Stock (PBM) Company Profile
Firmenname
Psyence Biomedical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare PBM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
3.17 | 7.57M | 0 | 1.52M | -1.14M | -6.3213 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine - Stocktwits
Jeffrey Weiner holds 59,750 shares in PSYENCE BIOMEDICAL LTD. (PBM) - Stock Titan
Psyence Biomedical Company Profile & Introduction - Moomoo
PBM News | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
Psyence Biomedical Corrects Technical Error in 2023 Equity Incentive Plan - TipRanks
Psyence Biomedical (PBM) corrects error in 2023 equity incentive plan - Stock Titan
Psyence Biomedical draws attention premarket after filing on 30% stake - Bez Kabli
Psyence Biomedical (PBM) Surges Over 7%: Bullish Momentum Builds Near ResistanceEnding Diagonal - newsline.com
Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake - TradingView
Psyence Labs gains 30.05% ownership of Psyence Biomedical (PBM) - Stock Titan
Psyence Biomedical Ltd. Warrant (PBMWW) Slides 8.94% as Stock Hovers at $0.03Market Cap Weight - The Legal Advocate
Psyence Biomedical (PBM) Rallies 5.85% as Shares Test Key Resistance Near $4.56Value Area High - The Legal Advocate
Psyence Biomedical Ltd. (PBM) Edges Higher Amid Sector Rotation and Key Technical LevelsUpthrust Pattern - The Legal Advocate
Psyence Biomedical Warrants (PBMWW) Edge Higher; Support and Resistance Converge at $0.03Momentum Breakout Ideas - The Legal Advocate
$Psyence Biomedical (PBM.US)$ picked me up lets goooo - Moomoo
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PBM Stock Chart | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
TradingKey - TradingKey
Is Psyence (PBMWW) stock hiding in plain sight? (+6.50%) 2026-05-08Theta Decay - newser.com
Psyence Biomedical Ltd. Common Shares (PBM) Live Share Price, Invest From India - INDmoney
12 Health Care Stocks Moving In Friday's Pre-Market SessionAkanda (NASDAQ:AKAN), Akari Therapeutics (N - Benzinga
Short sales on the TSX: What bearish investors are betting against - The Globe and Mail
Psyence Biomedical shares rise following equity investment agreement - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Why is Psyence Biomedical stock falling Wednesday? - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Psyence Biomedical doses first patient in psilocybin cancer trial By Investing.com - Investing.com Australia
PBM jumps on Trump psychedelic push, ibogaine supply story - MSN
Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial - TipRanks
Psyence BioMed (Nasdaq: PBM) doses first patient in NPX-5 Phase IIb trial - Stock Titan
Why Is Psyence Biomedical Stock Falling Wednesday? - Sahm
Psyence Biomedical doses first patient in psilocybin cancer trial - Investing.com
Psyence Biomedical (PBM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder - The Manila Times
Psyence Biomedical Ltd. Begins Phase IIb Clinical Trial for NPX-5 Psilocybin Treatment in Cancer Patients - Quiver Quantitative
PBMWW Psyence highlights clinical trial progress as core strategic priority in its latest quarterly earnings release.Community Watchlist - Cổng thông tin điện tử Tỉnh Sơn La
Why is Psyence Biomedical stock trading lower on Tuesday? - MSN
Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):